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ABSTRACT 
Back ground & objectives 
        The association of raised serum uric acid levels with various cardiovascular risk 
factors has often led to the debate of whether raised serum uric acid levels could be an 
independent risk factor in essential hypertension. Hence, we carried out a study to 
examine the possibility of hyperuricemia causing hypertension, to see if there is a 
relationship between the serum uric acid levels and severity & if they  had duration of 
hypertension. 
Methodology 
        The study was carried out in Coimbatore Medical College Hospital, the study period 
was of 12 months from December 2010 to November 2011. A total of 400 patients were 
studied of which 200 were cases and 200 were controls. 
       The patients were included if they satisfied the JNC VII criteria for hypertension. 
They were excluded if they were having any other condition known to cause raised serum 
uric acid levels & secondary hypertension. 
Results 
       The study showed that serum uric acid levels were raised in patients with 
hypertension in comparison to normotensives. The Mean SUA levels between cases and 
controls were 6.1125 ± 1.5662 and 5.6695 ± 1.3323 respectively with t-value = 3.05, p-
value = .002441.  
       SUA levels in the stages of hypertension showed a mean serum uric acid level in 
stage 1 hypertension of 5.5979  ± 1.4046 and stage 2 hypertension of 6.2750 ± 1.5836 
with the t-value of 2.65 and p-value = 0.0087 which was significant. 
       SUA level in patients with hypertension < 5 years was 5.175 ± 1.1188 and those with 
≥ 5 years was 6.9779 ± 1.4175 with the t-value of 9.93 and p-value = 0.0001 which was 
also significant. 
 
Interpretation & Conclusion 
      Based on the study carried out, we concluded that SUA can be used as an early 
biochemical marker to determine the severity and duration of hypertension. 
Key words: Serum Uric Acid; Hypertension; JNC VII; Hyperuricemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
INTRODUCTION 
 
                
             Hypertension is an important, increasing medical and public health problem.  
Worldwide prevalence estimates for hypertension may be as much as 1 billion 
individuals  and approximately 7.1 million deaths per year may be attributable to 
hypertension.(1)  
               The WHO reports that suboptimal blood pressure (>115 mm  of Hg Systolic 
BP) is  responsible for 62% of cerebrovascular disease and 49% of ischemic heart 
disease. In addition, suboptimal blood pressure is the number one attributable risk for 
death due to myocardial infarction, stroke, congestive heart failure, peripheral 
vascular disease and end stage renal disease throughout the world.(1)  
          Approximately 30% of adults are still unaware of their hypertension, more than 
40% of individuals are not on treatment, and two thirds of hypertensive patients are 
not being controlled to BP levels less than 140/90 mm of Hg.(1) 
                Uric acid, which serves no biochemical function other than being an end 
product of purine metabolism, was first discovered in 1776. A Swedish chemist 
Scheele isolated it from a urinary tract stone. In 1797, a British chemist Wallaston 
detected uric acid in a tophus  
which was removed from his own ear. About 50 years later Alfred Baring Garrod, a 
British physician showed by chemical isolation that uric acid was abnormally high in 
gouty patients.  
In subsequent studies Garrod formulated a rational relationship between 
hyperuricemia and symptomatology of gouty patients. 
           Association between hypertension and hyperuricemia was recognized when a 
family with a unique and unfortunate pedigree attended Hammer Smith hospital in 
 
 
1957. The father and six of the seven siblings of a patient had hyperuricemia, while 
his mother and all his siblings had hypertension.(1) This raised the question whether a 
raised serum uric acid was common in patients with hypertension. 
             Studies of uric acid levels and the development of hypertension have 
generally been consistent, continuous, and of similar magnitude. Hyperuricemia is 
also common among adults with prehypertension, especially when microalbuminuria 
is present. The observation that hyperuricemia precedes the development of 
hypertension indicates that it is not simply a result of hypertension per se.                     
           Several multivariate analytical studies have thrown light that an elevated uric 
acid level is an independent risk factor for cardiovascular disease after controlling for 
the contribution of established risk factors like age, obesity, smoking, Diabetes 
mellitus, alcohol consumption and physical inactivity.(2) Such convincing data from a 
developing country like ours is poorly known. This study was done to determine 
whether raised serum uric acid levels were an independent risk factor for developing 
hypertension in our Indian subcontinent. 
 
 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Objectives 
 
 
AIMS AND OBJECTIVES 
 
               - To study the relationship between serum uric acid levels and essential  
                 hypertension. 
 
              - To study the relationship between serum uric acid levels and duration of    
                hypertension. 
 
             - To study the relationship between serum uric acid levels and severity of  
               hypertension. 
 
 
 
 
 
 
 
 
         
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
 
REVIEW OF LITERATURE 
HYPERTENSION 
 
 
          Hypertension is the third leading killer disease in the world and is responsible 
for 1 in every 8 deaths. About 1 billion people are affected by hypertension 
worldwide.(3) The prevalence of hypertension is known to increase with age. Over 
50% of individuals aged 60 to 69 and over 75% of those aged 70 years and older are 
affected. Recent Framingham Heart Study reported that lifetime risk of developing 
HTN is approximately 90% for men and women who are normotensive at 55-65 years 
old and survived to the age of 80-85 years.(4) 
        Studies have shown that BP is an independent risk factor for CVD. This 
relationship is independent, consistent and continuous. Observations involving more 
than 1 million individuals have shown that death from both CVD and stroke increases 
progressively and linearly from BP levels of as low as 115mm systolic and 75 mm 
diastolic upwards. The increased risks are present in all age groups ranging from 40 to 
89 years old. For every increment of 20 mm hg systolic or 10mm diastolic there was a 
doubling of mortality from both ischemic heart disease and stroke.(5) 
        Evidence also warrants greater attention to the importance of SBP as a major risk 
factor for CVD. The rise in SBP continues throughout life, in contrast to DBP, which 
rises until approximately 50 years age, tends to level off over the next decade, and 
may remain same or fall later in life. Clinical trials have demonstrated that control of 
isolated systolic hypertension reduces total mortality, CV mortality, stroke and HF 
events.(6, 7) 
 
 
 
 
 
 
MECHANISMS OF HYPERTENSION 
 
1. INTRAVASCULAR VOLUME 
The initial elevation of blood pressure in response to vascular volume expansion is 
related to an increase of cardiac output; however, over time, peripheral resistance 
increases and cardiac output reverts toward normal. The mechanism for the “pressure-
natriuresis” phenomenon may involve a subtle increase of glomerular filtration rate, 
decreased absorbing capacity of the renal tubules, and possibly hormonal factors such 
as atrial natriuretic factor.(8) 
 
2. AUTONOMIC NERVOUS SYSTEM 
 
         The autonomic nervous system maintains cardiovascular homeostasis via 
pressure, volume and chemoreceptor signals. Adrenergic reflexes modulate blood 
pressure over the short term and adrenergic function, in concert with hormonal and 
volume-related factors, contributes to the long-term regulation of arterial pressure.(8) 
 
3. RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM 
 
 
        The renin-angiotensin-aldosterone system contributes to the regulation of arterial 
pressure primarily via the vasoconstrictor properties of angiotensin II and the sodium-
retaining properties of aldosterone.  
         Angiotensin II is a potent pressor substance, the primary trophic factor for the 
secretion of aldosterone by the adrenal zona glomerulosa, and a potent mitogen 
stimulating vascular smooth-muscle cell and myocyte growth. Independent of its 
hemodynamic effects, Angiotensin II may play a role in the pathogenesis of 
atherosclerosis through a direct cellular action on the vessel wall.(8) 
 
 
        Aldosterone also has effects on non-epithelial targets. Independent of a potential 
effect on blood pressure, aldosterone may also play a role in cardiac hypertrophy and 
CHF. 
RENIN - ANGIOTENSIN - ALDOSTERONE SYSTEM 
 
 
Fig.1-Renin Angiotensin Aldosterone system 
       Pathologic patterns of left ventricular geometry have also been associated with 
elevations of plasma aldosterone concentration in patients with essential hypertension, 
as well as in patients with primary aldosteronism. 
  
 
 
PATHOLOGIC CONSEQUENCES OF HYPERTENSION 
 
1. Heart 
              
              Hypertensive heart disease occurs as a result of structural and functional 
adaptations leading to left ventricular hypertrophy, diastolic dysfunction, CHF, 
abnormalities of blood flow due to atherosclerotic coronary artery disease and 
microvascular disease and cardiac arrhythmias. Diastolic dysfunction is an early 
consequence of hypertension related heart disease and is exacerbated by left 
ventricular hypertrophy and ischemia.(9,10) 
        Hypertension places increased tension on the left ventricular myocardium that is 
manifested as stiffness and hypertrophy, which accelerates the development of 
atherosclerosis within the coronary vessels. Abnormalities in Left Ventricular 
Function- the earliest functional changes in hypertension are in left ventricular 
diastolic dysfunction, with lower E/A ratio and longer isovolumic relaxation time.(9) 
Left Ventricular Hypertrophy- Hypertrophy as a response to the increased afterload 
associated with elevated systemic vascular resistance can be viewed. Variety of 
dysfunctions accompany LVH, including lower coronary vasodilatory capacity, 
depressed left ventricular wall mechanics, and abnormal left ventricular diastolic 
filling pattern.(10) 
Congestive Heart Failure- The various alterations of systolic and diastolic function 
seen with LVH can progress into congestive heart failure. A 20mm hg increment in 
systolic blood pressure conferred a 56% increased risk of CHF in the Framingham 
cohort. 
         When haemodynamically challenged by stress, persons with hypertension are 
unable to increase their end diastolic volume, because of decreased left ventricular 
relaxation and compliance. Consequently, a cascade begins, in which left ventricular 
 
 
end diastolic blood pressure rises, left atrial pressure increases and pulmonary edema 
develops.(11) 
 
    
                           Fig.2-Consequences of systolic and diastolic dysfunction 
                                                    related to hypertension(26) 
 
 
Coronary Heart Disease- Hypertension is a major risk factor for myocardial 
infarction and ischemia. Acute rise in blood pressure may follow the onset of 
ischaemic pain; the blood pressure often falls immediately after the infarct if pump 
function is impaired. Once MI occurs, the prognosis is affected by both the pre-
existing and the subsequent blood pressure. The prevalence of silent MI is 
 
 
significantly increased in hypertensive subjects, and they have a greater risk for 
mortality after an initial MI.(12) 
 
2. Brain 
 
               Hypertension is an important risk factor for brain infarction and 
haemorrhage. The incidence of stroke rises progressively with increasing blood 
pressure levels, particularly systolic blood pressure in individuals >65 years.(8). 
Hypertension is also associated with impaired cognition in an aged population. 
Hypertensive encephalopathy is related to failure of auto regulation of cerebral blood 
flow at the upper pressure limit, resulting in vasodilatation and hyperperfusion. 
Untreated hypertensive encephalopathy may progress to stupor, coma, seizures, and 
death within hours.(13) 
3. Kidney 
 
           Hypertension is a major risk factor for renal injury and ESRD. The increased 
risk associated with high blood pressure is graded, continuous and present throughout 
the entire distribution of blood pressure above optimal. Renal risk appears to be more 
closely related to systolic than to diastolic blood pressure.  
            The atherosclerotic, hypertension-related vascular lesions in the kidney 
primarily affect the preglomerular arterioles, resulting in ischemic changes in the 
glomeruli and postglomerular structures like renal tubules and collecting ducts. 
Glomerular pathology progresses to glomerulosclerosis, and eventually the renal 
tubules may also become ischemic and gradually atrophic. 
             Clinically, macroalbuminuria (a random urine albumin/ creatinine ratio > 300 
g/mg) or microalbuminuria (a random urine albumin / creatinine ratio 30-300 
g/mg) are early markers of renal injury.(8) 
 
 
            Microalbuminuria in hypertensive patients has been correlated with left 
ventricular hypertrophy and carotid artery thickness.(14) 
 
 
4. Peripheral Arteries & Eyes 
 
Hypertensive patients with arterial disease of the lower limbs are at increased 
risk for future cardiovascular disease. The ankle-brachial index is an useful approach 
for evaluating Peripheral Arterial Disease and is defined as the ratio of noninvasively 
assessed ankle to brachial (arm) systolic blood pressure. An ankle-brachial index         
< 0.90 is considered diagnostic of Peripheral Arterial Disease.  
          Vascular changes in the fundus of the eye reflect both hypertensive retinopathy 
and arteriosclerotic retinopathy. The hypertensive  retinal changes are graded by the  
Keith – Wegner – Barker classification as 
Grade 1  Mild to Moderate narrowing or sclerosis of the arterioles. 
Grade 2  Moderate to marked narrowing of the arterioles. Local and or  
generalized   narrowing of arterioles. Exaggeration of light reflex. 
Grade 3  Retinal arteriolar narrowing and focal constriction, retinal edema, 
Cotton wool  patches, haemorrhages. 
Grade 4  Grade 3 + Papilloedema. 
 
5.  Hypertension during Pregnancy 
 
          In about 12% of first pregnancies in previously normotensive women, 
hypertension appears after 20 weeks (gestational hypertension) and in about half this 
will progress to preeclampsia when complicated by proteinuria, edema or 
hematological or hepatic abnormalities, which in turn, increase the risk of progress to 
eclampsia, defined by the occurrence of convulsions. Women with hypertension 
predating pregnancy have an even higher incidence of preeclampsia and a greater 
 
 
likelihood of early delivery of small-for-gestational age babies. Preeclampsia is of 
unknown cause but occurs frequently in primigravid women and in pregnancies 
involving, either men or women who were the product of a pregnancy complicated by 
preeclampsia, supporting a genetic role.(15) 
 
DEFINING HYPERTENSION 
 
            The best operational definition for hypertension is “the level at which the 
benefits (minus the risks and costs) of action exceed the risks and costs (minus the 
benefits) of inaction.”(16) 
            From an epidemiologic perspective, there is no obvious level of blood pressure 
that defines hypertension. The multiple Risk Factor Intervention Trial (MRFIT), 
which included  > 350,000 male participants, demonstrated a continuous and graded 
influence of both systolic and diastolic blood pressure on CHD mortality. 
Cardiovascular disease risk doubles for every 20-mmHg increase in systolic and 10-
mmHg increase in diastolic pressure. Among older individuals, systolic blood 
pressure and pulse pressure are more powerful predictors of cardiovascular disease 
than diastolic blood pressure.(8,17) 
 
  
 
 
CLASSIFICATION OF BLOOD PRESSURE 
 
 
           Based on the seventh report of the Joint National Committee on prevention, 
detection, evaluation and treatment of high blood pressure (JNC VII report) BP is 
classified into the following stages : 
 
Classification of BP Systolic BP (mm of Hg) Diastolic BP (mm of Hg) 
Normal < 120 <80 
Prehypertension 120 - 139 80 - 89 
Stage 1 hypertension 140 - 159 90 - 99 
Stage 2 hypertension 160≥   100≥  
 
Table.1- Classification of BP for Adults > 18 years old 
 
 
            In contrast with the classification provided in the JNC VI report, a new 
category designated prehypertension has been added and stages 2 and 3 have been 
combined.(17) 
            Patients with prehypertension are at increased risk for progression to 
hypertension; those in the 130/80 to 139/89 mm hg BP range are at twice the risk to 
develop hypertension as those with lower values.(18) 
 
ACCURATE BLOOD PRESSURE MEASUREMENT 
 
          The accurate measurement of BP is the sine qua non for successful 
management. The equipment, whether aneroid, mercury or electronic, should be 
trained and regularly retrained in the standardized technique, and the patient must be 
properly prepared and positioned. The auscultatory method of BP measurement 
should be used. 
 
 
        Persons should be seated quietly for at least 5 minutes in a chair (rather than on 
an examination table), with feet on the floor, and arm supported at heart level. 
Caffeine, exercise and smoking should be avoided for at least 30 minutes prior to 
measurement.  
       Measurement of BP in the standing position is indicated periodically, especially 
in those who report symptoms consistent with reduced BP on standing. An 
appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
used to ensure accuracy. At least two measurements should be made and the average 
recorded.  
        For manual determinations, palpated radial pulse obliteration pressure should be 
used to estimate SBP. The cuff should then be inflated 20 to 30 mm Hg above this 
level for the auscultatory determinations. The cuff deflation rate for auscultatory 
readings should be 2 mm Hg per second. SBP is the point at which the first of two or 
more Korotkoff sounds is heard (onset of phase 1), and the disappearance of 
Korotkoff sound (onset of phase 5) is used to define  DBP. 
        In certain conditions like Aortic Regurgitation, the diastolic BP will be 0 mm Hg 
and the appearance of muffled sound is taken as diastolic BP. Care should be taken 
while measuring BP in elderly patients as there will be auscultatory gap. 
 
The key messages of JNC – VII are:(17) 
 
• In those older than age 50, SBP of greater than 140 mm Hg is a more  
important cardiovascular disease (CVD) risk factor than DBP. 
• Beginning at 115/75 mm Hg, CVD risk doubles for each increment of  20/10 
mm Hg. 
• Those who are normotensive  at 55 years of age will have a 90 life time risk of 
developing hypertension. 
 
 
Initial Blood Pressure, 
mm Hg* 
Follow-Up Recommended + 
 
Normal Recheck in 2 years 
Prehypertension Recheck in 1 year 
Stage 1 hypertension Confirm within 2 months# 
Stage 2 hypertension Evaluate or refer to source of care  within 1 month. For those 
with higher pressures  (eg., > 180/110 mm Hg), evaluate   and 
treat immediately or within 1  week depending on clinical  
situation and complications. 
 
Table.2-Recommendations for Follow-Up based on Initial Blood Pressure 
Measurements for Adults without Acute End Organ Damage (JNC-7) 
 
* If systolic and diastolic categories are different, follow recommendations for shorter 
time follow up (e.g, 160/86 mm Hg should be evaluated or referred to source of care 
within 1 month). 
 
+ Modify the scheduling of follow-up according to reliable information about past BP 
measurements, other cardiovascular risk factors, or target organ disease. 
 
# Provide advice about lifestyle modifications. 
      
  
CLASSIFICATION OF HYPERTENSION: 
           Patients with arterial hypertension and no definable cause are said to have 
Primary or essential or idiopathic hypertension. Individuals in whom a specific 
structural organ or gene defect is responsible for hypertension are defined as having a 
secondary form of hypertension.(19) 
  
 
 
Classification of Arterial Hypertension: 
- Systolic hypertension with wide pulse pressure 
     1. Decreased compliance of aorta (arteriosclerosis) 
     2. Increased stroke volume 
     3. Aortic regurgitation 
     4. Thyrotoxicosis 
     5. Hyperkinetic Heart Syndrome 
     6. Fever 
     7. Arteriovenous fistula 
     8. Patent Ductus Arteriosus 
- Systolic And Diastolic Hypertension  
  (Increased peripheral vascular resistance) 
    I. Renal 
          A. Chronic Pyelonephritis 
          B. Acute and chronic glomerulonephritis 
          C. Polycystic kidney disease 
          D. Renal artery stenosis or renal infarction 
          E. Other severe renal diseases (arteriolar nephrosclerosis, diabetic nephropathy,  
  etc.,) 
          F. Renin-producing tumors 
  II. Endocrine 
         A. Oral Contraceptives 
         B. Adrenocortical Hyperfunction 
             1. Cushing’s disease and syndrome 
             2. Primary hyperaldosteronism 
 
 
             3. Congenital or hereditary adrenogential syndromes. 
        C. Pheochromocytoma 
        D. Myxedema 
        E. Acromegaly 
III. Neurogenic 
       A. Psychogenic 
       B. Increased intracranial pressure (acute ) 
       C. Familial Dysautonomia (Riley-Day Syndrome ) 
       D. Polyneuritis (acute porphyria, lead poisoning) 
       E. Spinal cord section (acute) 
IV. Miscellaneous 
       A. Coarctation of aorta 
       B. Increased intravascular volume (excessive transfusion, Polycythemia Vera) 
       C. Polyarteritis Nodosa 
       D. Hypercalcemia 
       E. Medications e.g. Glucocorticoids, Cyclosporine.., 
V. Unknown etiology 
      A. Essential hypertension (>90% of all cases of hypertension) 
      B. Toxaemia of pregnancy 
      C. Acute intermittent porphyria 
GENETIC CONSIDERATIONS: 
        Essential hypertension is almost certainly a polygenic disorder, involving 
multiple genes, each having small effects on blood pressure. (20) 
  
 
 
NATURAL HISTORY OF UNTREATED HYPERTENSION: 
           Both the rising SBP and falling DBP levels logically are associated with an 
increased risk for atherosclerotic vascular diseases. The resultant widened pulse 
pressures have been widely reported to be the best prognostic indicator of 
cardiovascular risk. However, an analysis of data from one million adults in 61 
prospective studies found that, for predicting mortality from both stroke and coronary 
artery disease, the SBP is slightly more informative than DBP and that pulse pressure 
is much less informative.(21) 
 
SYMPTOMS AND SIGNS: 
         Uncomplicated hypertension is almost always asymptomatic, so that patient may 
be unaware of the consequent progressive cardiovascular damage for as long as 10 to 
20 years. 
         Symptoms often attributed to hypertension- Headache, tinnitus, dizziness and 
fainting may be observed just as commonly in the normotensive population. Many 
symptoms attributable to the elevated BP are psychogenic in origin, often reflecting 
hyperventilation induced by anxiety over the diagnosis of a lifelong, insidious disease 
that threatens well being and survival.(22) 
       When symptoms do bring the patient to the Physician, they fall into three 
categories. They are related to  
       (1) the elevated pressure itself  
       (2) the hypertensive vascular disease and  
       (3) the underlying disease, in the case of secondary hypertension.  
       Though popularly considered a symptom of elevated arterial pressure, headache 
is characteristic of only severe hypertension.  Most commonly such headaches are 
localized to the occipital region and are present when the patient awakens in the 
 
 
morning but subsides spontaneously after several hours. Other complaints that may be 
related to elevated blood pressure include dizziness, palpitations, easy fatigability, and 
impotence.  
        Complaints referable to vascular disease include epistaxis, hematuria, blurring of 
vision owing to retinal changes, episodes of weakness or dizziness due to transient 
cerebral ischemia, angina pectoris, and dyspnoea due to cardiac failure. Pain due to 
dissection of aorta or to a leaking aneurysm is a rare presenting symptom. 
        Examples of symptoms related to the underlying disease in secondary 
hypertension are polyuria, polydipsia, and muscle weakness secondary to 
hypokalemia in patients with primary aldosteronism or weight gain, and emotional 
lability in patients with Cushing’s syndrome. Patients with pheochromocytoma may 
present with episodic headaches, palpitations, diaphoresis, and postural dizziness.(23) 
ASSOCIATION OF HYPERTENSION WITH OTHER 
CONDITIONS: 
1. Obesity 
          Hypertension is more common among obese individuals and adds to their 
increased risk of IHD especially if it is abdominal/visceral in location as a part of the 
metabolic syndrome. In the Framingham Study the incidence of hypertension was 
increased 46 % in men and 75 % in female who are overweight defined as a body 
mass index of 25.0 to 29.9 compared to normal weight persons.(24) 
2. Physical Inactivity 
          Physical fitness can help prevent hypertension and persons who are already 
hypertensive can lower their BP by means of regular aerobic exercise. The 
relationship may involve a restoration of age related declines in endothelium 
dependent vasodilatation.(25) 
  
 
 
3. Alcohol Intake 
          Alcohol in large amounts (more than 2 portions a day and even more so when 
drunk in binges), alcohol increases BP and arterial stiffness. The pressor effect of 
larger amounts of alcohol primarily reflects an increase in cardiac output and heart 
rate, possibly a consequence of increased sympathetic nerve activity.  
          Alcohol also alters cell membrane and allows more calcium to enter perhaps by 
inhibition of sodium transport. 
4. Smoking 
         Cigarette smoking raise blood pressure, probably through the nicotine induced 
release of nor-epinephrine from adrenergic nerve endings.  
          Smoking also causes an acute and marked reduction in radical artery 
compliance, independent of  the risk of the increase in blood pressure. 
5. Sleep Apnea 
          Snoring and sleep are often associated with hypertension, which may in turn be 
induced by increased sympathetic activity and endothelin release in response to 
hypoxemia during apnea.  
           Relief of sleep apnea may alleviate hypertension.(26) 
6. Hematological Findings: 
          Higher haematocrits are found in hypertensive persons and associated with 
abnormal left ventricular filling on echocardiography.(27) 
7. Hypercholesterolemia: 
          Hypercholesterolemia frequently coexists with hypertension at least in part 
because it impairs endothelium dependent vasodilatation. Lipid lowering therapy 
restores the bioavailability of nitric oxide, reduces arterial stiffness and lowers BP.(28) 
 
 
 
8. Hyperuricemia 
 
            Raised serum uric acid concentrations in the blood are commonly encountered 
in essential hypertension. Although the raised serum uric acid and episodes of gout 
are occasionally attributable to therapy, asymptomatic hyperuricemia not infrequently 
precedes the diagnosis and treatment of essential hypertension. 
           The hyperuricemia observed in untreated hypertension may reflect the decrease 
in renal blood flow and early hypertensive nephrosclerosis. However, 
antihypertensive drug regimens, especially those including diuretics, do confound the 
link between hypertension-associated morbidity and mortality. 
          Epidemiological evidence to support the contention that uric acid is an 
independent risk factor for hypertension- associated morbidity can be gleaned from a 
multivariate analysis of 1988-94 data on 3900 hypertensive people from the public-
use database of the US National Health and Nutrition Survey (NHANES III). It 
showed that raised serum uric acid was associated with significantly higher sex-
adjusted risk of heart attack and stroke.                     
         Hypertensive people with raised serum uric acid had a significantly higher 
relative risk (RR) for both heart attack and stroke.(29) The NHANES III data supports 
the hypothesis that uric acid is an independent risk factor for hypertension-associated 
morbidity and mortality. 
         The renal handling of uric acid may provide a physiological clue to why 
hypertension-associated morbidity is closely linked to serum uric acid. It is well 
established that serum uric acid increases as arterial blood pressure rises and is 
associated with a reduction in renal blood flow. 
         High serum uric acid concentrations may increase sodium reabsorption at 
nephron sites proximal to the distal tubule, and it has been proposed that metabolic 
 
 
perturbations such as hyperinsulinaemia may mediate some of the effects of 
hypertension. 
          Hyperuricaemia may represent a multimetabolic syndrome in which insulin-
mediated renal haemodynamic abnormalities lead to hypertensive renal damage. It 
seems safe to say that hyperuricaemia in hypertension may be an early indicator of 
hypertensive cardiorenal disease, which is commonly associated with a 
multimetabolic syndrome.(30) 
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URIC ACID  METABOLISM 
 
          Uric acid is the final breakdown product of purine degradation in humans. 
Urates, the ionized forms of uric acid, predominate in plasma extracellular fluid and 
synovial fluid, with ~98% existing as monosodium urate at pH 7.4.(20) 
         The pH of urine greatly influences the solubility of uric acid. Although purine 
nucleotides are synthesized and degraded in all tissues, urate is produced only in 
tissues that contain xanthine oxidase, primarily the liver and small intestine. Urate 
production varies with the purine content of the diet and the rates of purine 
biosynthesis, degradation, and salvage. Normally, two-third to three-fourth of urate is 
excreted by the kidney, and most of the remainder is eliminated through the intestine. 
        The kidneys clear urate from the plasma and maintain physiologic balance by 
utilizing specific organic anion transporters (OATs) including urate transporter 1 
(URATI) and human uric acid transporter (hUAT). URAT1and other OATs carry 
urate into the tubular cells from the apical side of the lumen. Once inside the cell, 
urate must pass to the basolateral side of the lumen in a process controlled by the 
voltage-dependent carrier hUAT.  
      Until recently, component model has been used to describe the renal handling of 
urate / uric acid. The methods are 
       (1) Glomerular filtration, 
       (2) Tubular reabsorption 
       (3) Secretion, and 
       (4) Postsecretory reabsorption. 
     URAT1 is a novel transporter expressed at the apical brush border of the proximal 
nephron. Uric acid compounds directly inhibit URAT1 on the apical side of the 
tubular cell (so-called cis-inhibition).(20) 
 The total-body urate pool is the net result between urate production
excretion. 
         Urate production is influenced by dietary intake of purines and the
novo biosynthesis of purines from nonpurine precursors,
salvaging phosphoribosyl
by urinary and intestinal routes.
         Hyperuricemia can be caused by increased product
combination of mechanisms. When hyperurice
deposit in tissues as tophi.
Fig.4-URIC ACID TURNOVER AND METABOLISM
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urate in plasma, 415 umol/L (6.8 mg/dL). In epidemiologic studies, hyperuricemia is 
defined as the mean plus 2 standard deviations of values determined from a randomly 
selected healthy population. When measured in unselected individuals, 95% have 
serum urate concentrations <420 umol/L (7.0 mg/dL).  
         Finally, hyperuricemia can be defined in relation to the risk of disease. The risk 
of developing gouty arthritis or urolithiasis increases with urate levels >420 umol/L 
(7.0 mg/dL) and escalates in proportion to the degree of elevation. 
        Hyperuricemia is present in between 2.0 and 13.2% of ambulatory adults and 
somewhat more frequently in hospitalized individuals.(31) 
Causes of Hyperuricemia 
Hyperuricemia may be classified as primary or secondary depending on whether the 
cause is innate or is the result of an acquired disorder. However it is useful to classify 
hyperuricemia in relation to the underlying  pathophysiology, i.e., whether it results 
from increased urate production, decreased excretion, or a combination of two. 
Classification of Hyperuricemia by Pathophysiology 
1) Urate overproduction 
a. Primary idiopathic 
b. HPRT deficiency 
c. PRPP synthetase overactivity 
d. Hemolytic process 
e. Lmphoproliferative diseases 
f. Myeloproliferative diseases 
g. Polycythemia vera 
h. Psoriasis 
i. Paget’s disease 
 
 
j. Glycogenosis III, V, and VII 
k. Rhabdomyolysis 
l. Exersice 
m. Alcohol 
n. Obesity 
o. Purine-rich diet 
2) Decreased Uric acid Excretion 
a. Primary idiopathic 
b. Renal insufficiency 
c. Polycystic kidney disease 
d. Diabetic insipidus 
e. Hypertension 
f. Acidosis 
i. Lactic acidosis 
ii. Diabetic ketoacidosis 
g. Starvation ketosis 
h. Berylliosis 
i. Sarcoidosis 
j. Lead intoxication 
k. Hyperparathyroidism 
l. Hypothyroidism 
m. Toxaemia of pregnancy 
n. Bartter’s syndrome 
o. Down syndrome 
p. Drug ingestion 
 
 
i. Salicylates (>2g/d) 
ii. Diuretics 
iii. Alcohol 
iv. Levodopa 
v. Ethambutol 
vi. Pyrazinamide 
vii. Nicotinic acid 
viii. Cyclosporine 
3) Combined Mechanism 
a. Glucose-6- phosphatase deficiency 
b. Fructose-1- phosphate aldolase deficiency 
c. Alcohol 
d. Shock 
INCREASED URATE PRODUCTION 
 
        Diet provides an exogenous source of purines and, accordingly, contributes to 
the serum urate in proportion to its purine content. Strict restriction of purine intake 
reduces the mean serum urate level by about 60 umol/L (1.0 mg/dL) and urinary uric 
acid excretion by approximately 1.2 mmol/d (200 mg/d). Because about 50% of 
ingested RNA purine and 25% of ingested DNA purine appear in the urine as uric 
acid, foods high in nucleic acid content have a significant effect on the serum urate 
level. Such foods include liver, "sweetbreads" (i.e., thymus and pancreas), kidney, and 
anchovy. 
          Endogenous sources of purine production also influence the serum urate level. 
De novo purine biosynthesis, the formation of a purine ring from nonring structures, 
is an 11-step process that results in formation of inosine monophosphate (IMP). The 
 first step combines phosphoribosylpyrophosphate
catalyzed by amidophosphoribosyltransferase
biosynthesis and urate production are determined, for the most part, by this enzyme. 
AmidoPRT is regulated by th
and by the end products of biosynthesis (IMP and other ribonucleotides), which 
provide feedback inhibition.
Fig.5- De novo biosynthesis and metabolism of Purine nucleotides
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1. Phosphoribosylpyrophosphate(PRPP) synthetase 
2. Amidophosphoribosyltransferase (amidoPRT)  
3. Adenylosuccinate lyase 
4. (myo-)adenylate (AMP) deaminase   
5. 5’-nucleotidase 
6. Adenosine deaminase 
7. Purine nucleoside phosphorylase 
8. Hypoxanthine phosphoribosyltransferase (HPRT) 
9. Adeenine phosphoribosyltransferase (APRT) 
10. Xanthine oxidase    
 
          A secondary regulatory pathway is the salvage of purine bases by hypoxanthine 
phosphoribosyltransferase (HPRT). HPRT catalyzes the combination of the purine 
bases hypoxanthine and guanine with PRPP to form the respective ribonucleotides 
IMP and guanosine monophosphate (GMP). Increased salvage activity thus retards 
de novo synthesis by reducing PRPP levels and increasing concentrations of 
inhibitory ribonucleotides.(31) 
        Serum urate levels are closely coupled to the rates of de novo purine 
biosynthesis, which is driven in part by the level of PRPP, as evidenced by two 
inborn errors of purine metabolism. Both increased PRPP synthetase activity and 
HPRT deficiency are associated with overproduction of purines, hyperuricemia, and 
hyperuricaciduria.  
        An X-linked disorder that causes an increase in activity of the enzyme PRPP 
synthetase leads to increased PRPP production and accelerated de novo biosynthesis. 
PRPP is a substrate and allosteric activator of amidoPRT, the first enzyme in the de 
novo pathway.             
 
 
        HPRT deficiency is also X-linked and enhances urate biosynthesis in two ways. 
PRPP is accumulated as a result of decreased utilization in the salvage pathway and, 
in turn, provides increased substrate for amidoPRT and de novo biosynthesis. In 
addition, decreased formation of the nucleoside monophosphates, IMP and GMP, via 
the salvage pathway impairs feedback inhibition on amidoPRT, further enhancing de 
novo biosynthesis. 
           Accelerated purine nucleotide degradation can also cause hyperuricemia, i.e., 
with conditions of rapid cell turnover, proliferation, or cell death, as in leukemic blast 
crises, cytotoxic therapy for malignancy, hemolysis, or rhabdomyolysis. Nucleic acids 
released from cells are hydrolyzed by the sequential activities of nucleases and 
phosphodiesterases, forming nucleoside monophosphates, which in turn are degraded 
to nucleosides, bases and urate.              
        Hyperuricemia can result from excessive degradation of skeletal muscle ATP 
after strenuous physical exercise or status epilepticus and in glycogen storage diseases 
types III, V, and VII. The hyperuricemia of myocardial infarction, smoke inhalation 
and acute respiratory failure may also be related to accelerated breakdown of ATP.(31) 
Decreased Uric Acid Excretion 
 
         Over 90% of individuals with sustained hyperuricemia have a defect in the renal 
handling of uric acid. In hyperuricemia with gout the renal defect is evidenced by a 
lower than normal ratio of urate clearance to glomerular filtration rate (or urate to 
insulin clearance rate) over a wide range of filtered loads. As a result, gouty 
individuals excrete approximately 40% less uric acid than nongouty individuals for 
any given plasma urate concentration.  
      Uric acid excretion increases in gouty and nongouty individuals when plasma 
urate levels are raised by purine ingestion or infusion, but in those with gout, plasma 
 
 
urate concentrations must be 60 to 120 umol/L (1 to 2 mg/dL) higher than normal to 
achieve equivalent uric acid excretion rates.(31) Altered uric acid excretion could 
theoretically result from decreased glomerular filtration, decreased tubular secretion, 
or enhanced tubular reabsorption. Decreased urate filtration does not appear to cause 
primary hyperuricemia but does contribute to the hyperuricemia of renal 
insufficiency. 
        Although hyperuricemia is invariably present in chronic renal disease, the 
correlation between serum creatinine, urea nitrogen, and urate concentration is poor. 
Uric acid excretion per unit of glomerular filtration rate increases progressively with 
chronic renal insufficiency, but tubular secretory capacity tends to be preserved, 
tubular reabsorptive capacity is reduced, and extrarenal clearance of uric acid 
increases as renal damage becomes more severe. Decreased tubular secretion of urate 
causes the secondary hyperuricemia of acidosis.  
        Diabetic ketoacidosis, starvation, ethanol intoxication, lactic acidosis, and 
salicylate intoxication are accompanied by accumulations of organic acids (β- 
hydroxybutyrate, acetoacetate, lactate, or salicylates) that compete with urate for 
tubular secretion.        
       Hyperuricemia may be due to enhanced reabsorption of uric acid distal to the site 
of secretion. This mechanism is known to be responsible for the hyperuricemia of 
extracellular volume depletion that occurs with diabetes insipidus  or diuretic 
therapy.(31) 
Combined Mechanisms 
       Both increased urate production and decreased uric acid excretion may contribute 
to hyperuricemia. Individuals with a deficiency of glucose-6- phosphatase, the 
enzyme that hydrolyzes glucose-6-phosphate to glucose, are hyperuricemic from 
 
 
infancy and develop gout early in life. Increased urate production results from 
accelerated ATP degradation during fasting or hypoglycemia. In addition, the lower 
levels of nucleoside monophosphates decrease feedback inhibition of amidoPRT, 
thereby accelerating de novo biosynthesis. Glucose-6-phosphatase-deficient 
individuals may also develop hyperlacticacidemia, which blocks uric acid excretion 
by decreasing tubular secretion. 
       Patients with hereditary fructose intolerance caused by fructose-1-phosphate 
aldolase deficiency also develop hyperuricemia by both mechanisms. In 
homozygotes, vomiting and hypoglycemia after fructose ingestion can lead to hepatic 
failure and proximal renal tubular dysfunction. Ingestion of fructose, the substrate for 
the enzyme, causes accumulation of fructose-1-phosphate. This action results in ATP 
depletion, accelerated purine nucleotide catabolism, and hyperuricemia. Both lactic 
acidosis and renal tubular acidosis contribute to urate retention. Heterozygous carriers 
develop hyperuricemia, and perhaps one-third develop gout. The heterozygous state 
has a prevalence of 0.5 to 1.5%, suggesting that fructose-1-phosphate aldolase 
deficiency may be a relatively common cause of familial gout.(31) 
       Alcohol also promotes hyperuricemia by both mechanisms. Excessive alcohol 
consumption accelerates hepatic breakdown of ATP and increases urate production. 
Alcohol consumption can also induce hyperlacticacidemia, which blocks uric acid 
secretion. The higher purine content in some alcoholic beverages such as beer may 
also be a factor. 
 
                     
  
 
 
COMPLICATIONS OF HYPERURICAEMIA 
 
Hyperuricaemia and Gout: 
 
        The most recognized complication of hyperuricemia is gouty arthritis. In the 
general population the prevalence of hyperuricemia ranges between 2.0 and 13.2%, 
and the prevalence of gout is between 1.3 and 3.7%. The higher the serum urate level, 
the more likely an individual is to develop gout. In one study, the incidence of gout 
was 4.9% for individuals with serum urate concentrations >540 umol/L (9.0 mg/dL) 
compared with 0.5% for those with values between 415 and 535 umol/L (7.0 and 8.9 
mg/dL). The complications of gout correlate with both the duration and severity of 
hyperuricemia. 
Hyperuricaemia and Renal System: 
 
  Hyperuricemia also causes several renal problems: 
    1. Nephrolithiasis; 
    2. Urate nephropathy, a rare cause of renal insufficiency attributed to monosodium 
urate  crystal deposition in the renal interstitium; and 
   3. Uric acid nephropathy, a reversible cause of acute renal failure resulting from  
deposition   of large amounts of uric acid crystals in the renal collecting ducts, pelvis, 
and ureters. 
Hyperuricaemia and Syndrome X: 
 
        Syndrome X is characterized by abdominal adiposity with visceral adiposity, 
impaired glucose tolerance due to insulin resistance with hyperinsulinaemia, 
hypertriglyceridemia, increased low density lipoprotein cholesterol, decreased high 
density lipoprotein cholesterol, and hyperuricemia. 
      Hyperinsulinaemia reduces the renal excretion of uric acid and sodium. Not 
surprisingly, 
 
 
hyperuricaemia resulting from euglycaemic hyperinsulinaemia may precede the onset 
of type 2 diabetes, hypertension, coronary artery disease, and gout in individuals with 
syndrome X.(31) 
Increased SUA levels in Hypertension 
 
        The mechanisms underlying the increase in SUA and its potential prognostic 
implications in patients with essential hypertension are still not completely known. 
Uric acid, a final product of purine metabolism, is bound  5% to plasma proteins, is 
freely filtered at the glomerulus as a function of renal blood flow, is 99% reabsorbed 
in the proximal tubule, secreted by the distal tubule, and subjected to considerable 
postsecretory reabsorption. Fractional secretion of uric acid is about 7% to 10%. A 
direct association exists between SUA and renal vascular resistance in subjects with 
essential hypertension.(32) 
       Uric acid is also commonly associated with hypertension. It is present in 25% of 
untreated hypertensive subjects, in 50% of subjects taking diuretics, and in >75% of 
subjects with malignant hypertension.  
       The increase in serum uric acid in hypertension may be due to the decrease in 
renal blood flow that accompanies the hypertensive state, since a low renal blood flow 
will stimulate urate reabsorption. 
       Hypertension also results in microvascular disease, and this can lead to local 
tissue ischemia.(33) In addition to the release of lactate that blocks urate secretion in 
the proximal tubule, ischemia also results in increased uric acid synthesis. With 
ischemia, ATP is degraded to adenine and xanthine, and there is also increased 
generation of xanthine oxidase. The increased availability of substrate (xanthine) and 
enzyme (xanthine oxidase) results in increased uric acid generation as well as oxidant 
(O2 -) formation. The finding that ischemia results in an increase in uric acid levels 
 
 
may also account for why uric acid is increased in preeclampsia and congestive heart 
failure.(34) 
        Other factors may also contribute to why uric acid is associated with 
hypertension, including alcohol abuse, lead intoxication, obesity and insulin resistance 
and diuretic use. 
        The observation that an elevated uric acid is associated with subjects at 
cardiovascular risk may account for why hyperuricemia predicts the development of 
cardiovascular disease in the general population, in subjects with hypertension  and in 
subjects with preexisting cardiovascular disease. Hyperuricemia also predicts stroke 
in diabetic and nondiabetic subjects and predicts the development of hypertension and 
renal disease in the general population.(35,36) Also, hyperuricemia is a novel, 
independent risk factor for heart failure.(37) 
 
 
 
 
 
 
 
 
  
 
 
 
 
HISTORY OF URIC ACID AND HYPERTENSION 
 
         The concept that uric acid may be involved in hypertension is not a new one. In 
fact, in the paper published in 1879 that originally described essential hypertension, 
Frederick Akbar Mohamed noted that many of his subjects came from gouty families. 
He hypothesized that uric acid might be integral to the development of essential 
hypertension.(38) 
        Ten years later, this hypothesis re-emerged when Haig(39) proposed low-purine 
diets as a means to prevent hypertension and vascular disease. In 1909, the French 
academician Henri Huchard noted that renal arteriolosclerosis (the histological lesion 
of hypertension) was observed in three groups: Those with gout, those with lead 
poisoning, and those who have a diet enriched with fatty meat. All of these groups are 
associated with hyperuricemia.(40) The association between elevated serum uric acid 
and hypertension was observed and reported repeatedly in the 1950s to 1980 but 
received relatively little sustained attention because of the lack of a mechanistic 
explanation.(41-43) 
        Twenty-five to 40% of adult patients with hypertension have hyperuricemia          
(> 6.5 mg/dl), and this number increases dramatically when serum uric acid in the 
high-normal range is included.(19,20) In preeclampsia, the correlation between 
elevated serum uric acid and hypertension is > 70%.(44)  
       Despite these observations, the lack of a causal mechanism led to mild elevations 
of serum uric acid being largely ignored in medical practice. The strength of the 
relationship between uric acid level and hypertension decreases with increasing 
patient age and duration of hypertension, suggesting that uric acid may be most 
important in younger subjects with early-onset hypertension.(43) 
 
 
       Cross-sectional studies have consistently noted that more than a quarter of 
patients with untreated hypertension have elevated serum UA.(45,46) Serum UA levels 
have also been  associated cross-sectionally with BP(43,47,48) and longitudinally with 
hypertension incidence (49-53) and future increases in BP.(54) 
Mild hyperuricemia in the Rat - an animal model for essential hypertension 
        The study of mild hyperuricemia required an animal model before the lack of 
any mechanistic detail that had plagued the hypothesis over 100 years could be 
addressed. In the late 1990s, Johnson and Colleagues(55) developed a model using a 
pharmacologic inhibitor of urate oxidase, oxonic acid, that allows the study of 
sustained mild hyperuricemia.            
       When fed 2% oxonic acid in their standard diet, Sprague-Dawley rats have an 
increase of mean serum uric acid concentrations from 0.5 to 1.4 g/dl to 1.7 to 3.0 
mg/dl. During a 7-wk treatment period, systolic BP increases an average of 22 mmHg. 
The increase in BP can be prevented entirely by the co-administration of the xanthine 
oxidase inhibitor allopurinol or by the uricosuric agent benziodarone, indicating 
linearly related to the rise in uric acid (r = 0.77). 
        Histologic evaluation of the renal tissue of the hyperuricemic, hypertensive rats 
reveals an expansion of the vascular smooth muscle and narrowing of the lumina of 
the afferent arterioles leading to endothelial dysfunction.(56) It is interesting that the 
development of arteriolosclerosis can be prevented using allopurinol to control uric 
acid levels. However, hydrochlorothiazide, which normalizes BP without lowering 
serum uric acid, does not prevent the development of arteriolosclerosis, indicating that 
uric acid, not hypertension, is the causative stimulus.(46,57) 
       These experimental results indicate that mild hyperuricemia induces renal 
inflammation, activation of the renin-angiotensin system and down regulation of nitric 
 
 
oxide production, all of which are potentially important pathways that lead to uric 
acid-mediated hypertension. In short, mild hyperuricemia leads to an irreversible salt-
sensitive hypertension over time. Recent in vitro studies also have elucidated the 
possible mechanism of uric acid-mediated arteriolosclerosis. Primary human vascular 
smooth muscle cells (HVSMC) are induced to proliferate by addition of uric acid to 
the growth medium in a dose-dependent manner.(58)     
     The human smooth muscle cells express the urate-transport channel URAT1 as 
evidenced by both Northern and Western analyses. Consistent with this observation, 
cultured HVSMC rapidly take up C-urate and blockade of this uptake by probenecid 
attenuates the uric acid-mediated induction of proliferation in a dose-dependent 
manner.(59) Signaling studies have revealed further the possible mechanism by which 
urate uptake leads to HVSMC proliferation.(58,60,61) 
The effect of uric acid on vascular smooth muscle cells (VSMC) 
       Uric acid is taken up through the probenecid-sensitive urate transport channel 
URAT1. This leads to mitogen-activated protein kinase activation and extracellular 
signal-regulated kinase 1 and 2 phosphorylation. In turn, transcription factors NF-
k(nuclear transcription factor) and AP1 are activated leading to increased cyclo-
oxygenase-2 (COX-2) expression and activity. The COX-2 product Thromboxane A2 
mediates increased expression and elaboration of platelet derived growth factor 
(PDGF) and monocyte chemoattractant protein-1 (MCP-1), which induce VSMC 
proliferation and macrophage infiltration respectively.(58,60,61,62) 
  
 
 
REMNANT KIDNEY MODEL 
 
       Various studies have investigated the effect of uric acid on multiple mechanisms 
of progressive renal injury. In the remnant kidney model, hyperuricemic remnant 
kidney rats (caused by addition of 2% oxonic acid to their diets) had higher BP, 
greater proteinuria, and higher serum creatinine.(63,64) Addition of oxonic acid to 
cyclosporine treatment led to higher uric acid levels, more severe arteriolar hyalinosis, 
macrophage infiltration, and tubulointerstitial damage compared with rats that were 
treated with cyclosporine alone.(65) Furthermore treatment of cyclosporine-exposed 
rats with allopurinol improves GFR and in human liver transplant patients who were 
receiving cyclosporine, treatment with allopurinol resulted in improved renal 
function.(66,67) 
RECENT EPIDEMIOLOGY: A CHANGE IN PERSPECTIVE 
 
Before 1990, only Khan et al.(51) had reported that an increased serum uric 
acid is an independent risk factor for hypertension; however, it had been noted that 25 
to 40% of adults with hypertension have serum uric acid > 6.5 mg/dl and >60% have 
a serum uric acid > 5.5 mg/dl and that there was a linear relationship between serum 
uric acid and systolic BP.(68) 
       Three reports indicated that serum uric acid is an independent risk factor for 
hypertension were published in the 1990s(53,68,69) and many more were published in 
the past 10 yrs.(70-72) 
  
 
 
 
Author Year  published Study  size Follow-up Relative Risk 
Kahn et al.(27) 1972 10000  males 5 Years 2 - fold risk 
Selby et al.(26) 1990 2062  adults 6 Years 3 - fold risk 
Hunt et al.(29) 1991 1482  adults 7 Years 2 - fold risk 
Jossa et al.(25) 1994 619  males 12 Years 2 - fold risk 
Taniguchi et al.(42) 2001 6356  males 10 Years 2 - fold risk 
Masuo et al.(30) 2003 433  males 5 Years 
+27 mmHg in 
systolic BP per each 
1-mg/dL change in 
uric acid 
Nakanishi et al.(28) 2003 2310  males 6 Years 1.6 - fold risk 
Nagahama et al.(49) 2004 4489  adults 13 Years 1.7 - fold risk 
Alper et al.(43) 2005 577  children 11 Years Increased risk 
Sundstrom et al.(44) 2005 3329  adults 4 Years 1.6 fold risk 
 
Table.3-Studies on Relative Risk for Hypertension in Hyperuricaemia 
                      
  
 
 
SIR BRADFORD HILL’S CRITERIA FOR URIC ACID AS A 
CAUSAL FACTOR IN HYPERTENSION(73) 
 
1. Strength. In most studies an elevated uric acid predicts approximately a 2-fold 
increase in the frequency of hypertension after 5 to 10 years.(74-82) 
2. Consistency. An elevated uric acid was found in all 9 studies to be predictive 
for hypertension.(74-82) 
3. Specificity. The risk for developing hypertension with an elevated uric acid 
level remains after controlling for other cardiovascular risk factors.(75-82)New 
onset essential hypertension in adolescents is also associated with an elevated 
uric acid (UA ≥ 5.5 mg/dL) in the vast majority (about 90%) of cases; 
whereas it is present in only 30% of secondary hypertension and is rare in 
normotensive and white-coat hypertensive adolescent subjects.(83) 
4. Temporality. An elevated uric acid often precedes the development of 
hypertension, both in children and in adults.(74-82) 
5. Dose-dependent. The relationship of serum uric acid to future hypertension is 
continuous and dose-dependent.(74-82) 
6. Plausibility. A biological mechanism has been found by which raising uric 
acid may cause hypertension.(84-87) 
7. Coherence. The increase in hypertension frequency with Westernized diets 
corresponds to the rise in the frequency of hyperuricemia and gout.(88) 
8. Experiment. Experimental hyperuricemia causes hypertension in rats; 
preventing the rise in uric acid prevents the development of hypertension.(84-86) 
 
 
 
 
Koch’s Postulates for Uric Acid as a Causal Factor of Hypertension 
1. An elevated uric acid predicts the development of hypertension                            
(see Table.3).(74-81) 
2. An elevated uric acid is observed in 89% of new onset essential hypertension 
in adolescents and the level of uric acid correlates closely (r = 0.8) with the 
systolic BP.(83) 
3. Raising serum uric acid in rats results in the hemodynamic, pathological, and 
clinical characteristics of essential hypertension in humans.(84-86) 
4. A plausible biological mechanism has been shown in which uric acid induces 
a salt-resistant hypertension by inhibition of endothelial function and 
activation of the renin-angiotensin system, and a later salt-sensitive renal 
dependent hypertension by inducing microvascular disease(84-86); these 
changes are consistent with studies of hypertension in humans.(87) 
5. Lowering uric acid in hyperuricemic rats prevents or treats new onset 
hypertension in rats.(84). Pilot studies in humans also suggest lowering uric 
acid may lower BP in new onset essential hypertension in adolescents.(89) 
6. The recent evaluation of a subset of the Framingham Heart Study found that 
serum uric acid level was an independent predictor of hypertension and BP 
progression over as little as 4 years.(72) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uric acid and essential hypertension in children 
 
         In adolescents, the association between elevated serum uric acid and the onset of 
essential hypertension is even more striking. The Moscow Children’s Hypertension 
study found hyperuricemia (> 8.0 mg/dl) in 9.5% of children with normal BP, 49% of 
children with borderline hypertension, and 73% of children with moderate and severe 
hypertension.(90) 
        The Hungarian Children’s Health Study followed all 17,624 children who were 
born in Budapest in 1964 for 13yrs and found that significant risk factors for the 
development of hypertension were elevated heart rate, early sexual maturity and 
hyperuricemia.(91) 
       Gruskin compared adolescents (13 to 18yrs of age) who had essential 
hypertension with age-matched healthy control subjects and who had normal BP. The 
hypertensive children had both elevated serum uric acid (mean > 6.5 mg/dl) and 
higher peripheral renin activity.(92) 
        Feig and Johnson observed that the mean serum uric acid level (± SD) in control 
subjects and children with white coat hypertension were nearly identical but slightly 
higher in secondary hypertension (4.3 ±1.4 mg/dl, respectively; P = 0.80) but very 
high in children with primary hypertension (6.7 ±1.3 mg/dl; P = 0.004) (38). There was 
a tight, linear correlation between the serum uric acid levels and the systolic and 
diastolic BP in patients who were referred for evaluation of hypertension  (r = 0.8 for 
systolic BP and r = 0.6 for diastolic BP).(48) 
       Among patients who were referred for evaluation of hypertension, a serum uric 
acid > 5.5 mg/dl had an 89% positive predictive value for essential hypertension, 
whereas a serum uric acid level <5.0 had a negative predictive value for essential 
hypertension of 96%.(48) 
 
 
Evidences linking uric acid and hypertension 
 
1. An elevated uric acid level consistently predicts the development of 
hypertension.(51-53,68,69) 
2. An elevated uric acid level is observed in 25-60% of patients with untreated 
essential hypertension and in nearly 90% of adolescents with essential 
hypertension of recent onset.(48) 
3. Raising the uric acid level in rodents results in hypertension with the clinical, 
hemodynamic, and histologic characteristics of hypertension.(55) 
4. Reducing the uric acid level with xanthine oxidase inhibitors lowers blood 
pressure in adolescents with hypertension of recent onset.(67) 
         The identification of a biological mechanism by which uric acid could cause 
hypertension in humans has led to a renewed interest in the role of uric acid in 
hypertension. Indeed, there are now 10 studies that have examined whether an 
elevated uric acid level predicts the development of hypertension, and all found uric 
acid predictive. 
        The Bogalusa Heart study, found that uric acid levels in childhood predict the 
development of diastolic hypertension 10 years later.  
        The second study, from the Framingham group(72), also found uric acid to predict 
the development of hypertension. This latter study is all the more remarkable as it was 
performed in an older population (mean age of 50) in which they first eliminated 25% 
of their subjects because they already had hypertension or gout, thereby removing a 
large proportion of their target population. 
 
 
 
 
 
 
 
 
            PROPOSED MECHANISM FOR URIC ACID MEDIATED  
 
                                HYPERTENSION IN HUMANS 
 
        
  Excessive intake of fructose or purine-rich meats or exposure to low doses of 
lead may result in chronic hyperuricemia.(93) 
       Mothers with high uric acid levels that are the result of diet or conditions such 
as preexisting hypertension, obesity, or preeclampsia may transfer uric acid into the 
fetal circulation through the placenta, which may ultimately contribute to intrauterine 
growth retardation (IUGR) and a reduction in nephron number. 
       Among babies born with a low nephron number, hyperuricemia may develop 
in childhood because of genetic or environmental factors.  
       Chronic hyperuricemia would stimulate the renin-angiotensin system and 
inhibit release of endothelial nitric oxide contributing to renal vasoconstriction and 
possibly increasing blood pressure. 
       Persistent renal vasoconstriction may contribute to arteriolosclerosis and the 
development of salt-sensitive hypertension, even if the hyperuricemia is corrected. 
Thus in the later stage, hypertension becomes salt sensitive but resistant to uricosuric 
therapy i.e., even after the correction of higher serum uric acid levels, there will be 
persistant hypertension which will be amenable to conventional anti-hypertensive 
therapy.   
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Materials and Methods 
 
 
MATERIALS AND METHODS 
 
 
Study Setting 
Coimbatore Medical College Hospital, Coimbatore. The collaborative 
department was Department of Biochemistry, Coimbatore Medical College. 
Study design 
       Case – control study 
Period of study 
      December 2010 to November  2011. 
Ethical Committee Approval 
     The study was approved by the Ethical Committee, Coimbatore Medical College, 
Coimbatore. 
Patient Population 
Cases 
         Two hundred adults aged between 20-80 years were selected for the study from 
the Hypertension OPD of Coimbatore Medical College Hospital. They were studied 
for Serum Uric acid levels. 
Controls 
       Normotensive controls (n = 200) aged between 20-80 years were selected for the 
study and evaluated for clinical and laboratory data. 
      Both males and females were included for the study. All subjects and controls had 
normal renal function (Renal biochemistry, USG Abdomen). 
      Both groups are matched for both age and sex. 
  
 
 
Inclusion Criteria 
1. Age group between 20 to 80 years. 
2. Both sexes were included. 
3. Stage 1 and stage 2 Hypertension according to JNC-VII without any target end 
organ damage. 
Exclusion Criteria 
1. Hypertensive patients with Target End Organ damage 
a) Hypertensive Heart disease as evidenced by Left Ventricular hypertrophy on 
ECG- voltage criteria / Hypertensive crisis / Malignant Hypertension. 
b) Hypertensive Nephropathy 
c) Hypertensive Retinopathy 
2. Diabetes Mellitus – Type 1 and Type 2 or metabolic syndrome 
3. Patients with Chronic kidney disease. 
4. Hypertensive Patients with known Cerebro vascular disease. 
5. Hypertensive Patients with coronary Artery disease – Myocardial Ischemia or 
Infarction. 
6. Patients with long term drug intake like steroids, Anti-Tuberculous Treatment 
(ATT), diuretics, antimetabolite or chemotherapy drugs. 
7. Patients who were regularly consuming alcohol – Alcohol dependence 
subjects –  Evidenced by History, liver function tests and USG Abdomen. 
8. Patients with  Lympho or Myelo-proliferative disorders. 
9. Patients who had chronic liver disease and metabolic disorders. 
10. All causes of secondary Hypertension. 
11. Psoriasis / Gout. 
12. Patients in whom BMI >30. 
 
 
Consent 
         The study groups identified by the above criteria (inclusion and exclusion) were 
first informed about the nature of the study. Participants willing for the study were 
selected after getting an informed and written consent from them. 
        Thus, a total of 200 patients were taken up for study who satisfied the inclusion 
and exclusion criteria. Similarly, 100 age and sex matched subjects were kept as 
control. 
       There was no conflict of interest and financial support was Nil. Urinary excretion 
and urate clearance were not done, only serum uric acid levels were analysed. 
Patient profile 
      Selected socio-demographic, clinical and laboratory data were collected from the 
cases and controls and recorded in proforma. 
1. Socio-demographic profile 
Ø Age 
Ø Sex 
Ø Occupation. 
Ø Cardiovascular risk factors – smoking, family history 
2. Clinical profile 
Ø Body weight 
Ø Height 
Ø Body mass index 
Ø Waist circumference 
Ø Pulse 
Ø Systolic and diastolic blood pressure – Average of 3 BP measurements 
Ø Clinical examination 
 
 
3.Laboratory Data 
       Laboratory analyses, performed in Biochemical laboratory at the Coimbatore 
Medical College Hospital, Coimbatore included blood tests for the evaluation of 
renal parameters, fasting blood sugar, serum electrolytes, uric acid, lipid profile, 
thyroid function tests. 
Ø Complete urinalyses were performed by the pathological faculty. 
Ø ECG was taken for all the subjects and controls to rule out coronary artery 
disease and left ventricular hypertrophy. 
Ø Fundus examination was done for all subjects to rule out Hypertensive 
Retinopathy. 
Data collection and measurements: 
        The clinical examination consisted of a medical history, a physical examination, 
blood pressure measurement and anthropometric measurements. Laboratory data 
included  measurement of fasting serum uric acid levels and other parameters like 
Blood haemogram, Renal function tests (blood urea, serum creatinine), 
Electrocardiogram, Chest X-ray, Lipid profile (Total cholesterol, triglycerides, HDL- 
cholesterol, LDL- cholesterol), urine for protein and sugar. 
      The patients were asked to fast for 12 hours and to avoid smoking and heavy 
physical exercise for more than 2 hours before the examinations. After a 5 min rest in 
a quiet room, systolic and diastolic blood pressures were measured in the sitting 
position twice at an interval of a five minutes on the right arm with a standard 
mercury sphygmomanometer on three separate occasions.(94) 
       Anthropometric measurements included height and body weight, which were 
measured while the subject was wearing light clothing without shoes. The body mass 
index was calculated as the weight in kilograms divided by the height in m2. 
 
 
HYPERTENSION 
        Hypertension was defined according to the JNC VII classification of 
hypertension as those with SBP of < 120 mm hg and DBP of < 80 mm hg as 
normal, those with SBP of 120- 139 mm hg or DBP of 80 - 89 mm hg were labelled  
pre-hypertensive were not taken up for the study, those with SBP 140 - 159 mm hg 
or DBP of 90 - 99 mm hg were labeled as having Stage 1 hypertension, and those 
with SBP ≥ 160 mm Hg or DBP ≥ 100 mm hg were labeled as Stage 2 
hypertension. 
 
Method of Uric Acid estimation 
 
Principle 
         
       The principle for the determination of Serum Uric Levels was devised by Trivedi 
and Kabasakalian with a modified Trinder peroxidase method using TBHB. 
 
     URIC ACID + O2 + H2O         Uricase         Allantoin + CO2 + H2O2 
     H2O2 + 4- AAP + TBHB     Peroxidase        Quinoneimine + H2O 
    
The Sample used was unhemolyzed serum or plasma separated from the cells 
as soon as possible. Recommended anticoagulants are heparin and EDTA. Uric acid is 
stable in serum or urine for 3 days at 20 - 25o C. The intensity of chromogen 
(Quinoneimine) formed is proportional to the uric acid concentration in the sample 
when measured at 510 nm (510 -550nm) on biochromatic analysers against reagent 
blank. 
Reference Values for SUA levels - 
 
In Males : 3.4 - 7.0 mg/dL 
In females : 2.4 - 6.0 mg/dL 
 
 
 
STATISTICAL ANALYSIS 
     Data was entered in Microsoft excel spread sheet and analyzed statistically using 
SPSS 10.0 software package. Significance testing of the difference between means 
was done by unpaired 2 tailed student ‘t’-test for independent samples, and 
correlations were assessed by Pearson coefficient. Significance was considered, if the 
‘p’ value was below 0.05. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations and Results 
 
 
 
OBSERVATIONS AND RESULTS 
         During the 12 month study period from December 2010 to November 2011 a 
total of 400 patients were studied of which 200 patients were cases who were 
categorized into Stage 1 or Stage 2 hypertension (base on JNC VII classification) and 
200 were controls who were patients without hypertension or any other condition 
known to cause raised serum uric acid levels.  
                                           AGE DISTRIBUTION: 
       
       AGE GROUP 
               
                 CASES 
          
           CONTROLS 
       20 - 29                 2                  3 
       30 - 39               19                20 
       40 - 49               53                52 
       50 - 59               69                67 
       60 - 69               51                52 
       70 - 79                 6                  6 
 
Table.4- AGE DISTRIBUTION OF CASES AND CONTROLS 
Among the studied population, three-fourth of  people fall in the age groups 
between 40 – 69 years of age.  
Only one-fourth of people fall in the extreme ages of studied population. 
All the age groups in both cases and controls were matched well with subtle 
variations. 
 
 Fig.7-AGE DISTRIBUTION AMONG
                                               
CATEGORY
CASES
CONTROLS
        
Table
 
Among the cases, total number of male patients were 143 and total number of female 
patients were 57. 
    Among the controls, total number of male patients were 145 and total number of 
female patients were 55.
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The Serum Uric Acid levels in 
female cases ranged from 3.8 mg/dl to 9.6mg/dl.
The Serum Uric Acid levels in male controls ranged from 3.0 
female controls ranged from 2.8 
 
 SUA LEVELS BETWEEN
 
The total number of cases were 200 (both male and female), the data analysis 
of the cases showed the mean SUA level to be 6.1125 with a standard deviation of 
1.5662 (6.1125 ± 1.5662). 
 
.8-Sex Distribution of Cases and Controls 
male cases ranged from 3.2 mg/dl to 9.8 mg/dl
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        The total number of controls were 200 (both male and f
analyzed showed a mean SUA level of 5.6695 with a standard deviation of 1.3323 
(5.6695 ± 1.3323). 
Table.6-
 
Fig.9-Mean SUA Levels between Cases and Controls
The t-value was found to be 3.05 and 
significant. This showed that there was a significant rise in serum uric acid 
patients with hypertension when compared to normotensives.
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SUA AND RISK
               
Fig.10
 
The severity of hypertension was divided into stage 1 and stage 2 based on
VII classification of hypertension. In the study done at our hospital the total number 
of patients assessed to have stage 1 hypertension was 48 patients (both male and 
female patients) and the total number of patients having stage 2 hypertension w
152(both male and female patients).
        
 
Stage of hypertention
 
 
Stage 1 
 
Stage 2 
 
                                                        
                                                           
                              Table.7
 
 BASED ON SEVERITY OF HYPERTENSION
-Distribution of stage of HT among cases
 
 
 
Number 
 
48 
 
152 
    t-value = 2.65 
p value = 0.0087 
-Mean SUA among the stages of hypertension
48
152
STAGE OF HYPERTENSION
Stage 1 HT
Stage 2 HT
 
 
 
 the JNC 
as 
 
SUA MEAN ± SD 
(mg/dL) 
 
5.5979 ± 1.4046 
 
6.2750 ± 1.5836 
 
  
   The data analysis for SUA levels in the stages of hypertension showed a mean 
serum uric acid level in stage 1 hypertension of 5.5979 with a standard deviation of ± 
1.4046. 
        The mean serum uric acid levels in stage 2 hypertensive patient were 6.2750 with 
a standard deviation of  ± 1.5836.
 
Fig.11
 
          The t-value was 2.65 and 
analysed showed that there was a significant rise in serum uric acid in patients who 
were having stage 2 hypertension i.e. those with a SBP 
Hg than those with stage 1 hypertension with a SBP 140
Hg. 
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         The duration of hypertension was divided into 2 categories 
hypertension for duration of hypertension < 
hypertension≥ 5 years.
        The total number of patients with hypertension for duration of < 5 years was 96  
and the total number of patients with duration of hypertension 
 
                    
Fig.12-Pati
The mean SUA level in patients with hypertension < 5 years was 5.175 with a 
standard deviation of  ± 1.1188.
The mean SUA level in patients with hypertension 
standard deviation of ± 1.4175.
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Fig.13-Mean SUA 
 
         The analyzed data showed a t
showed that there is significant increase in SUA levels in patients with hypertension
5 years than those with a duration of < 5 years.
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Discussion 
 
 
DISCUSSION 
 
Elevated SUA levels have been associated with an increased risk for 
cardiovascular disease. The potential mechanisms by which SUA may directly cause 
cardiovascular risk include enhanced platelet aggregation and inflammatory activation 
of the endothelium.(95) 
            In few studies, the association of SUA with cardiovascular disease was 
uncertain after multivariate adjustment as in the Framingham Heart Study (1985) and 
the ARIC study (1996), but in others the association remained certain and significant. 
            Because elevated serum uric acid is correlated with several risk factors 
including renal dysfunction, hypertension, insulin resistance, hyperhomocysteinemia 
and hyperlipidemia, it is debated whether SUA is an independent cardiovascular risk 
factor. 
           In the present study the incidence of hyperuricemia in controls was 21% 
and the incidence of hyperuricemia in cases was 38 %. 
          Various other studies have also shown that increased SUA levels were seen in 
hypertensive patients. Kinsey (1961) in his study with 400 hypertensive patients 
reported a  46 % incidence of hyperuricemia in hypertensives (43). Kolbe (1965) in 
his study of 46 hypertensive patients found 26 to be having increased SUA levels 
(56 %).(96) 
            A. Breckenridge (1966) showed 274 of 470 patients on antihypertensive 
treatment (58%) had raised SUA levels and 90 of the 333 patients (27%) attending the 
clinic for the first time had hyperuricemia(1). In a study by C. J. Bulpitt (1975), 48 % 
male hypertensives and 40 % female hypertensives had their SUA level in the 
hyperuricemic range.(97) 
 
 
           Ramsay (1979) in his study of 73 men with untreated hypertension had 18 with 
raised serum uric acid levels (25%).(98) Messerli et al (1980) had an incidence of 72 % 
raised SUA in their study population of 39 established hypertensives. Messerli and 
Frohlich et al hypothesized that the frequent presence of hyperuricemia in 
hypertensive patients reflects underlying renal dysfunction or reduced renal 
perfusion.(99) 
             It certainly is possible that uric acid may be an earlier and more sensitive 
marker of decreased renal blood flow than serum creatinine. It has been recently 
suggested that since uric acid may play a role in the formation of free radicals and 
oxidative stress, the increased risk of hypertension in subjects with raised serum uric 
acid levels might be associated with this increased generation of free radicals. Several 
observations support this concept of free radical mediated inhibition of endothelium 
dependent vasodilatation. An antioxidant deficiency in diet which produces 
hyperuricemia, contributes to the aetiology of hypertension, and the antioxidant drugs 
also show a blood pressure lowering effect in both diabetic and hypertensive 
patients.(100) 
           In a study by Tykarski (1991), he showed SUA concentration and the 
prevalence of hyperuricemia were significantly higher in hypertensive patients. They 
further demonstrated that tubular secretion of uric acid was significantly lower in 
hypertensive patients in comparison with normotensive subjects. There was no 
difference in pre and post- secretory reabsorption of uric acid. They concluded that 
high prevalence of hyperuricemia in essential hypertension was caused by impaired 
renal excretion of uric acid.(101) 
 
 
Goldstein and Manowitz (1993) showed in an adolescent population that, with 
age, weight, height and sexual maturity controlled, SUA significantly predicted blood 
pressure even in adolescents.(102) 
Three possible conclusions can be drawn from the association of hypertension 
with raised SUA levels -. 
         Hypertension may arise as a result of hyperuricemia, 
         Hypertension can cause hyperuricemia and  
        The duration and severity of hypertension is related directly to the SUA levels. 
In gouty patients without advanced tophi, however renal failure and 
hypertension are rare. In a group of 80 patients attending the Hammer Smith hospital 
gout clinic only 2 were hypertensive. In a study of gouty patients of Northern India by 
Kumar et al they found that only one out of 30 patients had hypertension.(103) Fessel et 
al showed no appreciable loss of renal function in patients with gout as compared to 
normal subjects followed up for 12 years.(104) In a study by Lawrence E Ramsay there 
was no evidence that hyperuricemia had a deleterious effect on renal function.(98) 
Canon et al considered that an impairment of renal function will raise the SUA levels 
more commonly than an increased SUA will cause renal damage.(105) 
      Hence it is unlikely that hypertension arises as a result of raised SUA levels, 
but the possibility that uric acid which plays a role in the formation of free radicals 
and oxidative stress, the increased risk of hypertension in subjects with raised serum 
uric acid levels might be associated with this increased generation of free radicals. 
Hence the fact that raised SUA levels can lead to Hypertension cannot be entirely 
ruled out. 
    As to the possibility that Hypertension can cause hyperuricemia, it is thought 
that hyperuricemia can result from either overproduction of uric acid or from under 
 
 
excretion of uric acid. Overproduction of uric acid can be measured by the rate of 
incorporation of acid precursors such as Glycine labeled N 15, into the uric acid pool. 
Such a study carried out in 4 hypertensive patients with raised SUA levels did not 
show any overproduction of uric acid. 
     In the study of Breckenridge, excretion of uric acid and uric acid clearance 
were lower in all hypertensive patients than in the normal group. When the uric acid 
clearance was expressed per 100ml of glomerular filtrate, there was no significant 
difference between normal subjects and hypertensive patients who had normal SUA 
levels, but the difference between those 2 groups and the hyperuricemic hypertensives 
was significant and they suggested a renal tubular abnormality in the handling of uric 
acid, the nature of the abnormality was not clear. 
         Later Messerli et al showed that hyperuricemia in hypertension is due to early 
renal vascular involvement, namely, Nephrosclerosis. SUA rises because of impaired 
renal tubular function, which is the main site of regulation of SUA due to 
nephrosclerosis. Tykarski in his study showed that SUA levels in hypertensives are 
due to impaired tubular secretion of urate. In the present study incidence and severity 
of hyperuricemia between cases and controls correlated significantly with the severity 
of hypertension. This correlated with both Kinsey and Breckenridge studies, but 
according to Cannon et al(105) severity of hypertension had no relation to SUA level.  
        Our study agrees with the study of Tykarski et al in that there is a 
positive correlation between SUA and severity of hypertension.(99) As to the 
possibility as to whether SUA levels was related to the severity and duration of 
hypertension, Breckenridge(42) in his study showed an increasing incidence of 
hyperuricemia as the diastolic BP increased in his study, but there was no tendency 
for hyperuricemia to occur, only with patients with more severe hypertension. 
 
 
Kinskey also found that hyperuricemia was common in patients with more severe 
grades of hypertension. Comparison showed that SUA increased significantly with 
duration of hypertension in our study. This was similar to the finding of Tykarski 
et al who encountered positive correlation between duration of hypertension and SUA 
in their study. 
      The PIUMA study demonstrates a strong independent association between 
SUA and CV risk in initially untreated and asymptomatic adult subjects with essential 
hypertension, but it is unable to answer the question of whether SUA exerts direct 
toxic effects. As extensively reviewed by Puig and Ruilope,(106) both uric acid and 
superoxide radicals are produced for the effect of xanthine oxidase in the late phase of 
purine metabolism. Superoxide radicals, which may cause tissue and vascular 
damage(107) are increased in subjects with essential hypertension.(108) 
       It would be important to clarify whether such increase is due, at least in part, 
to enhanced xanthine oxidase activity and whether inhibition of this enzyme by 
allopurinol may reduce CV risk.(109) 
      In our study we found that there is definite relation in SUA levels between 
hypertensive patients and normotensive patients and there is a directly proportional 
relation in the levels of SUA in relation to the duration and severity of 
hypertension. Hence the possibility of serum uric acid acting by the production of 
free radicals and causing oxidative stress leading to hypertension and whether the 
duration and severity of hypertension lead to renal dysfunction in the form of 
nephrosclerosis leading to higher levels of serum uric acid has to be considered as 
various other studies have also show to have a positive relation in the SUA levels and 
hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
 
 
 
CONCLUSION 
 
           The study showed the SUA levels are increased in hypertensives compared to 
normotensives. With the results based on the study carried out we concluded that there 
can be a direct relation between hyperuricemia and hypertension.  
          
Also the study showed that the SUA levels were significantly increased in 
patients with Stage-2 hypertension in comparison with those with stage-1 
hypertension, showing that the severity of hypertension also related to the SUA levels.  
         
The study also showed that the duration of hypertension had a significant 
impact on the SUA levels, those with a longer duration of hypertension had 
significantly raised SUA levels when compared with those of a lesser duration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
  
 
 
SUMMARY 
 
         Serum uric acid levels were measured in 400 patients both outpatient and in-
patients attending Coimbatore Medical College Hospital. The 400 patients were 
divided into 200 cases who were again divided again into categories based on severity 
of hypertension into stage 1 and stage 2 and duration of  <5 years and  ≥ 5 years. 
       The study showed a rise in SUA levels in cases with a  highly significant               
p = 0.002441 when compared to that of controls. The mean serum uric acid in cases 
and controls were 6.1125 ± 1.5662  and 5.6695 ± 1.3323 respectively. 
       The incidence of hyperuricemia in case and controls were 38% and 21% 
respectively. 
       A positive correlation was found between the severity of hypertension, the 
patients who were found to be having stage 2 hypertension had an increase in SUA 
levels which was highly significant p= .0087 when compared with those with stage 1 
hypertension. The mean SUA in patients with stage 1 hypertension was 5.5979 ± 
1.4046 and those with stage 2 hypertension was 6.2750 ± 1.5836. 
     We also found a positive correlation between SUA levels and the duration of 
hypertension patients with a duration of hypertension ≥ 5 years had a significant 
increase in the SUA levels p=  < 0.0001 than those patients with hypertension for a 
duration of <5 years. The mean SUA in patients <5 years was 5.1750 ± 1.1188 and 
those with duration of  ≥ 5 years was 6.9779 ± 1.4175. 
    As it has been shown that hyperuricemia is observed in untreated hypertension 
may be due to a decrease in the renal blood flow and early nephrosclerosis, 
unexplained rise in SUA levels in Essential Hypertension can be used as a simple 
biochemical marker in determining the severity and duration of hypertension. 
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Annexures 
 
 
 
 
 
PROFORMA 
SERUM URIC ACID IN ESSENTIAL HYPERTENSION 
Name :                                                                                              OP / IP No. : 
Age :                                                                                                 Hospital : CMCH 
Sex :                                                                                                 Unit : 
Occupation :                                                                                   Date : 
Address : 
 
Presenting Complaint : 
 
Duration of Hypertension : 
Treatment History : 
 
Past History :                 Diabetes mellitus / IHD / Stroke 
Family History :            Diabetes mellitus / IHD / Stroke 
Personal History :         Tobacco - Smoking : Yes/No 
                                                                           Quantity : 
                                                                           Duration : 
                                                         Chewing : Yes/No 
                                                                           Quantity : 
                                                                           Duration : 
                                           Alcohol Consumption : Yes/No 
                                                                           Quantity : 
                                                                           Duration : 
Diet :                                Veg/Non-Veg 
 
 
Micturition : 
Bowel Habits : 
Menstrual History : 
 
General Physical Examination : 
                                         Pallor 
                                         Clubbing 
                                         Oedema 
                                         Cyanosis 
                                         Icterus 
                                         Xanthoma 
                                         Arcus senilis 
                                         Tophi 
                                         Arthritis 
Pulse :                              Rate :            /min. 
                                         Rhythm : 
                                         Character : 
                                         Volume : 
                                         Condition of vessel wall: 
                                         Other peripheral pulses: 
BP                       (Sitting) : 1.                mm Hg      (Standing) : 1.                mm Hg 
                                             2.                mm Hg.                            2.                mm Hg 
                                             3.                 mm Hg                            3.                mm Hg 
 
Respiratory rate:               /min                                          Temperature :          0 F 
 
 
JVP :  
Height :                cms.                                                        Weight :               Kgs 
BMI : 
 
Systemic Examination : 
                       CVS : 
 
                       RS : 
 
                       Abdomen : 
 
                       CNS : 
 
                      Fundoscopy : 
 
INVESTIGATIONS:- 
Blood Routine :               Hb % - 
                                          TotalCount - 
                                          Differential Count - N    %; L    %; EMB     % 
                                          ESR - 
Urine Examination :      Albumin : 
                                          Sugar : 
                                          Microscopy : 
Blood Sugar :                   mg/dL 
Serum Uric Acid :                mg/dL 
 
 
Serum Urea :                        mg/dL 
Serum Creatinine :              mg/dL 
Lipid Profile :                   Total Cholesterol              mg/dL 
                                            LDL Cholesterol              mg/dL 
                                            HDL Cholesterol              mg/dL 
                                            Triglycerides                     mg/dl 
ECG : 
 
Chest X-ray : 
 
Comments : 
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MASTER CHART FOR CONTROLS 
 
Sl. 
No 
 
Name 
 
Age 
 
Sex 
 
IP/OP 
No 
 
SBP 
(mm of 
Hg) 
 
DBP 
(mm of 
Hg) 
 
SUA 
Levels 
(mg/dL) 
 
Category 
1 Ramalingam 60 M 111 120 82 3.8 Control 
2 Sivagami 55 F 1150 126 88 4.2 Control 
3 Cheraladhan 54 M 25636 110 80 4.0 Control 
4 Arun kumar 41 M 21265 122 76 4.4 Control 
5 Sundaram 63 M 23458 130 70 3.0 Control 
6 Kasinadhan 52 M 5645 128 74 4.4 Control 
7 Kumari 58 F 9283 124 70 4.0 Control 
8 Manivannan 38 M 37881 118 70 3.0 Control 
9 Ramaiyah 67 M 32431 120 78 4.0 Control 
10 Ponnusamy 69 M 53566 116 74 3.2 Control 
11 Veerasamy 61 M 70774 114 86 5.0 Control 
12 Marikozhundu 57 F 310 110 72 4.5 Control 
13 Velankanni 53 F 51423 108 72 3.6 Control 
14 Mumtaz 52 F 66111 110 70 5.0 Control 
15 Kesavan 48 M 67115 112 70 3.8 Control 
16 Jagadesh 44 M 1120 116 70 4.6 Control 
17 Sathish 41 M 42133 120 70 4.6 Control 
18 Ranjith 24 M 56780 130 76 4.2 Control 
19 Srirangan 49 M 41537 132 80 5.3 Control 
20 Parasuraman 63 M 57620 136 82 5.6 Control 
21 Ramasamy 69 M 115 130 84 6.0 Control 
22 Athiyappan 67 M 901 120 76 4.6 Control 
23 Sengodan 55 M 506 126 74 5.6 Control 
24 Kalimuthu 50 M 59871 120 70 4.6 Control 
25 Kamalakannan 40 M 62158 122 76 5.4 Control 
26 Thirupathi 38 M 41250 134 80 6.0 Control 
27 Sriram 32 M 47111 136 82 5.6 Control 
28 Marudhai 65 M 46956 130 88 5.2 Control 
29 Gopal 52 M 33119 110 80 5.6 Control 
30 Nallathangal 60 F 3141 112 78 5.2 Control 
31 Sasikumar 36 M 50507 110 70 5.8 Control 
32 Ramesh 28 M 61236 106 70 5.5 Control 
33 Nallasamy 78 M 85850 110 70 5.2 Control 
34 Srinivasan 70 M 8423 110 74 5.0 Control 
35 Sivanesan 56 M 62584 110 76 5.9 Control 
36 Thilagavathi 58 F 35425 120 74 5.6 Control 
37 Balu 54 M 56842 134 82 5.0 Control 
38 Krishnan 60 M 80258 136 80 6.4 Control 
39 Eswaran 66 M 15486 130 88 6.6 Control 
40 Dilli kumar 35 M 36541 132 80 6.0 Control 
 
 
41 Gowthaman 55 M 1026 104 68 5.0 Control 
42 Malliga 46 F 60150 110 74 6.4 Control 
43 Ravi kumar 41 M 81080 120 76 6.2 Control 
44 Chandran 39 M 65409 126 80 5.2 Control 
45 Gurumoorthi 68 M 7000 120 70 6.8 Control 
46 Ilamparithi 47 M 4100 116 74 6.6 Control 
47 Kuyilathal 60 F 5069 118 70 5.2 Control 
48 Rudhran 30 M 3756 110 74 6.6 Control 
49 Manickam 55 M 25401 104 70 6.8 Control 
50 Lilly 34 F 45630 102 68 6.8 Control 
51 Fathima 48 F 11279 104 70 2.8 Control 
52 Kadhar Ali 62 M 1569 100 68 4.0 Control 
53 Vinayagam 70 M 56423 100 70 3.6 Control 
54 Madhesh 39 M 8684 110 70 3.4 Control 
55 Pranesh 41 M 87153 124 76 3.0 Control 
56 Veerappan 50 M 1313 130 78 4.2 Control 
57 Prabakaran 52 M 17112 136 74 4.0 Control 
58 Badrinath 44 M 77066 124 70 7.6 Control 
59 Palani 61 M 50454 120 70 3.2 Control 
60 Alagusundaram 63 M 8056 122 78 7.6 Control 
61 Nallathambi 53 M 5552 134 74 4.0 Control 
62 Rajaganapathi 47 M 3496 130 70 3.2 Control 
63 Vellaiyammal 45 F 2985 124 70 4.5 Control 
64 Banu 48 F 82620 110 80 7.8 Control 
65 Senthamarai 39 F 228 100 66 4.2 Control 
66 Rasathi 34 F 3570 106 76 3.4 Control 
67 Kannan 54 M 1982 108 70 4.4 Control 
68 Dinesh 32 M 1108 104 68 8.4 Control 
69 Sudhakar 48 M 19841 110 70 4.5 Control 
70 Periyasamy 63 M 9051 100 66 4.2 Control 
71 Vinayagam 67 M 982 120 72 4.5 Control 
72 Abdul Rashid 74 M 1607 110 74 8.2 Control 
73 Natarajan 66 M 1987 100 70 4.4 Control 
74 Srinivasan 64 M 2703 104 70 4.5 Control 
75 Yasodha 48 F 20100 106 70 4.2 Control 
76 Nagarajan 59 M 12945 108 72 4.4 Control 
77 Padma 63 F 36001 100 70 4.8 Control 
78 Mariyappan 54 M 15008 110 68 4.2 Control 
79 Thayammal 57 F 60458 120 76 4.4 Control 
80 Sudharsanam 49 M 75308 126 72 4.4 Control 
81 Varadharaj 53 M 95004 122 70 5.2 Control 
82 Siddhaiyan 60 M 6024 132 80 4.2 Control 
83 Rangammal 65 F 20147 134 86 4.8 Control 
84 Jai Shankar 55 M 63254 124 80 4.8 Control 
85 Jayamani 50 F 12035 118 70 4.8 Control 
86 Rathinam 52 F 865 120 72 4.2 Control 
87 Manohar 40 M 958 126 76 4.2 Control 
88 Arunachalam 60 M 3657 100 74 5.6 Control 
 
 
89 Kalavathi 42 F 2359 138 76 5.2 Control 
90 Arumugam 58 M 11599 134 84 4.6 Control 
91 Radha 42 F 3357 132 80 5.8 Control 
92 Lalitha 56 F 77536 130 70 5.6 Control 
93 Elumalai 40 M 88541 124 70 4.4 Control 
94 Pavithra 43 F 75520 120 80 5.8 Control 
95 Archana 52 F 997 110 64 4.6 Control 
96 Prema 41 F 5150 110 70 4.6 Control 
97 Manjula 58 F 7466 110 70 6.2 Control 
98 Anandhan 55 M 12240 112 70 6.4 Control 
99 Ramachandran 62 M 3659 104 66 6.4 Control 
100 Kannaiyan 45 M 1227 108 68 4.4 Control 
101 Devaraj 48 M 4400 100 70 4.7 Control 
102 Uma 50 F 271 102 74 5.8 Control 
103 Soman 63 M 40006 100 70 4.8 Control 
104 Poornima 40 F 3617 104 70 4.6 Control 
105 Govindhan 70 M 1223 106 68 5.2 Control 
106 Varadharaj 59 M 69507 104 66 5.6 Control 
107 Sumathi 54 F 54027 118 74 5.4 Control 
108 Murugesh 45 M 91005 124 70 4.6 Control 
109 Renukadevi 37 F 75992 120 70 6.1 Control 
110 Rizwan 41 M 65783 134 78 4.6 Control 
111 Chinnathambi 47 M 33375 136 80 5.6 Control 
112 Indhumathi 39 F 56541 128 82 5.2 Control 
113 Rangachari 58 M 65810 122 74 6.2 Control 
114 Giridharan 66 M 69341 136 80 6.4 Control 
115 Karuppaiyah 54 M 77512 130 80 4.6 Control 
116 Pandiyan 48 M 63178 120 74 6.8 Control 
117 Noorun Tahira 50 F 36419 110 76 6.2 Control 
118 Vadvikarasi 54 F 912 130 78 5.2 Control 
119 Vijaya 58 F 4479 110 70 4.6 Control 
120 Kamala 66 F 11504 100 68 5.4 Control 
121 Muthu 52 M 10127 106 70 4.6 Control 
122 Raju 60 M 83657 104 70 5.6 Control 
123 Samikannu 47 M 88817 108 70 6.5 Control 
124 Samuel 62 M 94019 110 74 4.6 Control 
125 Mookan 66 M 43105 120 74 5.2 Control 
126 Elavarasan 42 M 4523 110 78 4.6 Control 
127 Kandhasamy 60 M 26226 104 72 6.2 Control 
128 Ibrahim 64 M 11985 126 80 5.6 Control 
129 Saraswathi 54 F 31042 128 80 6.9 Control 
130 Selvam 58 M 46028 134 84 6.8 Control 
131 Kalaiarasan 34 M 65283 132 86 6.6 Control 
132 Meenakshi 64 F 45861 136 86 4.6 Control 
133 Saravanan 56 M 1806 104 74 5.6 Control 
134 Thangavel 56 M 39420 100 72 6.6 Control 
135 Prakasam 66 M 25791 110 70 5.2 Control 
136 Ram kumar 48 M 22207 114 70 6.2 Control 
 
 
137 Sivashankar 42 M 29537 138 84 5.6 Control 
138 Karthikeyan 51 M 3549 130 80 6.6 Control 
139 Vargheese 60 M 67492 128 80 6.8 Control 
140 Rajeshwari 66 F 5128 130 74 5.0 Control 
141 Priya 42 F 20156 100 68 5.4 Control 
142 Sushila 43 F 35417 106 68 5.6 Control 
143 Singaram 53 M 15482 124 70 5.0 Control 
144 Mohan 59 M 20567 122 70 5.6 Control 
145 Subramani 67 M 9043 120 66 6.2 Control 
146 Senthil 45 M 91107 108 70 6.8 Control 
147 Appuraj 45 M 46505 100 64 6.4 Control 
148 Israel 44 M 20254 110 70 5.6 Control 
149 Ragupathi 66 M 98105 116 70 5.0 Control 
150 Bhavani 67 F 47100 130 78 6.2 Control 
151 Malarvizhi 48 F 60149 138 80 7.2 Control 
152 Kulandaivel 75 M 50661 134 82 7.0 Control 
153 Mayakkannan 50 M 1019 128 80 6.0 Control 
154 Kaasi 60 M 20114 120 78 7.4 Control 
155 Sugavanam 51 M 35048 110 70 7.5 Control 
156 Sodalaimadan 63 M 71651 120 76 6.0 Control 
157 Kuppannan 64 M 47960 126 76 7.4 Control 
158 Koodamalai 58 M 29811 130 78 6.0 Control 
159 Mathiyarasi 50 F 25189 122 70 6.0 Control 
160 Arthanari 48 M 91117 124 70 6.4 Control 
161 Thenappan 61 M 44819 120 68 7.0 Control 
162 Ponnuthayi 60 F 47335 110 66 7.2 Control 
163 Poovayi 57 F 41639 128 70 6.0 Control 
164 Karnan 55 M 97111 134 74 7.8 Control 
165 Dharman 56 M 96102 100 70 7.0 Control 
166 Shenbagam 49 F 1086 120 70 8.0 Control 
167 Ibrahim 47 M 1050 128 70 7.6 Control 
168 Sethuraman 59 M 81745 128 74 6.4 Control 
169 Rajeshwaran 57 M 63218 118 70 8.0 Control 
170 Aiyanar 55 M 30018 114 72 7.6 Control 
171 Younis Ahmed 56 M 46870 100 68 7.0 Control 
172 Thamarai 30 F 61279 112 70 6.0 Control 
173 Angamuthu 48 M 775 110 66 6.4 Control 
174 Pachamuthu 64 M 940 116 68 7.2 Control 
175 Bogar 66 M 1899 138 84 7.0 Control 
176 Kanagavalli 38 F 3347 134 80 6.4 Control 
177 Pandiyan 30 M 488 132 80 7.6 Control 
178 Allikodi 39 F 59217 122 70 8.0 Control 
179 Mahendran 28 M 36115 120 72 7.6 Control 
180 Gomathy 36 F 19113 126 74 7.2 Control 
181 Arulmurugan 44 M 88811 126 70 8.3 Control 
182 Moorthy 68 M 77113 128 74 6.0 Control 
183 Pichamuthu 61 M 51566 120 78 6.4 Control 
184 Gopinath 52 M 56300 110 68 7.6 Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
185 Navukarasu 50 M 67001 106 68 7.2 Control 
186 Sakthi 40 M 63611 108 70 8.0 Control 
187 Sathiyaseelan 49 M 66410 104 74 6.4 Control 
188 Selva kumar 43 M 18636 100 70 6.0 Control 
189 Balaji 47 M 10118 106 70 7.6 Control 
190 Sagayamary 56 F 52020 126 74 7.2 Control 
191 Yoganandham 49 M 59600 118 70 8.0 Control 
192 Nirmala 51 F 57116 104 70 8.2 Control 
193 Navaneedhan 60 M 96115 108 72 8.2 Control 
194 Kasirajan 63 M 20019 106 70 7.6 Control 
195 Vijaya 52 F 9194 124 74 7.2 Control 
196 Muralirajan 57 M 193 128 78 8.2 Control 
197 Manoharan 59 M 85580 134 76 8.2 Control 
198 Malarvannan 40 M 61793 138 80 7.2 Control 
199 Tamizhselvi 50 F 49317 130 82 3.6 Control 
200 Sanjeevi 55 M 1001 136 80 8.0 Control 
 
 
                                 KEY TO MASTER CHART 
 
 
              Sl.No - Serial number 
              IP - Inpatient 
             OP - Out patient 
             SBP - Systolic blood pressure 
             DBP - Diastolic blood pressure 
             SUA - Serum uric acid 
